Ultragenyx Pharmaceutical Inc. (RARE) Key Metrics
RARE valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.43B
- Enterprise value
- $824.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 2.0 10-yr median 16.2
- Price / book
- 19.7 10-yr median 6.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.35
RARE key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsRARE valuation Price multiples at each fiscal year-end price.
Price / sales−50.4%
3.4
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−9.7 pts
−20.8%
2025 · hover or tap a bar for each year
20162025
RARE returns How much profit the business earns on the capital it uses.
Return on invested capital
−448.2%
2025 · hover or tap a bar for each year
20162025
Return on assets+0.1 pts
−37.9%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin+5.1 pts
−70.1%
2025 · hover or tap a bar for each year
20162025
Asset turnover+18.5%
0.44
2025 · hover or tap a bar for each year
20162025
RARE per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+10.3%
$6.83
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$5.83
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$4.79
2025 · hover or tap a bar for each year
20162025
Book value per share
−$0.81
2025 · hover or tap a bar for each year
20162025
Shares outstanding+8.9%
98.6M
2025 · hover or tap a bar for each year
20162025
RARE financial health Debt, liquidity and how easily interest is covered.
Net debt+$1.2B
$583.0M
2025 · hover or tap a bar for each year
20162025
Current ratio+4.3%
2.48
2025 · hover or tap a bar for each year
20162025
Interest coverage
-8.6
2025 · hover or tap a bar for each year
20162025
Debt / assets+3,004.3%
0.83
2025 · hover or tap a bar for each year
20162025
RARE efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+13 days
76 days
2025 · hover or tap a bar for each year
20162025
Days of inventory−25 days
162 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−76 days
117 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle+63 days
122 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue−0.4 pts
0.9%
2025 · hover or tap a bar for each year
20162025
RARE valuation history
Fiscal year-endToday10-year median
RARE returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RARE debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RARE price vs earnings per share
Share price at year-endEPS (right axis)
RARE key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $2.27B | $3.81B | $3.52B | $3.24B | $5.70B | $8.42B | $2.42B | $2.16B | $1.97B | $2.78B |
| Enterprise value | $2.85B | $3.24B | $2.98B | $2.52B | $5.00B | $7.27B | $1.70B | $1.70B | $1.72B | $2.29B |
| Price / sales | 3.4 | 6.8 | 8.1 | 8.9 | 16.2 | 31.1 | 23.3 | 42.0 | 753.8 | — |
| Price / book | — | 14.9 | 12.8 | 9.2 | 6.2 | 7.3 | 3.7 | 3.6 | 5.1 | 5.9 |
| EV / sales | 4.2 | 5.8 | 6.9 | 6.9 | 14.2 | 26.8 | 16.4 | 33.1 | 660.2 | — |
| Earnings yield | −25.4% | −14.9% | −17.2% | −21.8% | −8.0% | −2.2% | −16.7% | −9.1% | −15.3% | −8.8% |
| Free cash flow yield | −20.8% | −11.1% | −14.8% | −16.3% | −7.2% | −2.1% | −15.3% | −13.6% | −13.0% | −6.1% |
| Dividend yield | — | — | — | — | — | — | — | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $23.00 | $42.07 | $47.82 | $46.33 | $84.09 | $138.43 | $42.71 | $43.48 | $46.38 | $70.31 |
| Per share | ||||||||||
| Revenue per share | $6.83 | $6.19 | $5.90 | $5.20 | $5.18 | $4.45 | $1.83 | $1.03 | $0.06 | $0.00 |
| Earnings per share | −$5.83 | −$6.29 | −$8.25 | −$10.12 | −$6.70 | −$3.07 | −$7.12 | −$3.97 | −$7.12 | −$6.21 |
| Operating cash flow per share | −$4.73 | −$4.57 | −$6.46 | −$5.44 | −$5.00 | −$2.17 | −$6.10 | −$5.84 | −$5.98 | −$4.07 |
| Free cash flow per share | −$4.79 | −$4.66 | −$7.09 | −$7.53 | −$6.07 | −$2.89 | −$6.54 | −$5.92 | −$6.05 | −$4.32 |
| Cash per share | $7.03 | $6.74 | $7.85 | $10.70 | $10.92 | $19.75 | $13.35 | $9.24 | $5.76 | $12.58 |
| Book value per share | −$0.81 | $2.82 | $3.74 | $5.04 | $13.61 | $18.97 | $11.56 | $12.23 | $9.03 | $11.97 |
| Tangible book value per share | −$3.04 | $0.36 | $0.88 | $2.12 | $11.02 | $16.09 | $8.49 | $8.74 | $4.65 | $11.97 |
| Dividends per share | — | — | — | — | — | — | — | — | $0.00 | $0.00 |
| Capex per share | $0.06 | $0.08 | $0.64 | $2.09 | $1.08 | $0.72 | $0.44 | $0.08 | $0.07 | $0.26 |
| Debt per share | $12.94 | $0.45 | $0.59 | $0.45 | $0.62 | $0.79 | $0.65 | — | $0.00 | $0.00 |
| Shares outstanding | 98.6M | 90.5M | 73.5M | 69.9M | 67.8M | 60.8M | 56.6M | 49.8M | 42.5M | 39.6M |
| Change in shares outstanding | +8.9% | +23.1% | +5.2% | +3.1% | +11.4% | +7.5% | +13.7% | +17.2% | +7.2% | +7.6% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | −214.5% | −193.2% | −111.0% | −43.7% | −20.6% | −63.8% | −39.8% | −70.5% | −48.9% |
| Return on invested capital (ROIC) | −448.2% | — | — | — | −267.6% | — | — | −203.6% | −452.5% | — |
| Return on assets (ROA) | −37.9% | −38.0% | −40.0% | −46.1% | −27.7% | −12.9% | −43.4% | −32.7% | −58.6% | −44.7% |
| Return on tangible assets | −43.8% | −44.4% | −47.4% | −52.8% | −33.7% | −11.8% | −41.9% | −36.2% | −99.1% | −45.5% |
| Free cash flow margin | −70.1% | −75.3% | −120.1% | −144.9% | −117.2% | −65.0% | −357.0% | −572.2% | — | — |
| Financial health | ||||||||||
| Total debt | $1.28B | $40.3M | $43.2M | $31.6M | $42.0M | $48.2M | $37.0M | — | $0 | $0 |
| Cash & short-term investments | $693.0M | $610.0M | $577.2M | $747.8M | $740.2M | $1.20B | $755.2M | $459.7M | $244.5M | $498.1M |
| Net debt | $583.0M | −$569.7M | −$534.0M | −$716.2M | −$698.2M | −$1.15B | −$718.2M | −$459.7M | −$244.5M | −$498.1M |
| Debt / equity | — | 0.16 | 0.16 | 0.09 | 0.05 | 0.04 | 0.06 | — | 0.00 | 0.00 |
| Debt / assets | 0.83 | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | — | 0.00 | 0.00 |
| Current ratio | 2.48 | 2.37 | 2.61 | 3.38 | 4.72 | 6.83 | 8.24 | 6.99 | 3.44 | 8.27 |
| Quick ratio | 2.34 | 2.24 | 2.49 | 3.28 | 4.63 | 6.76 | 8.13 | 6.90 | 3.43 | 8.27 |
| Interest coverage | -8.6 | -8.5 | -8.6 | -15.1 | -13.0 | -9.9 | -373.7 | — | — | — |
| Working capital | $567.0M | $473.0M | $451.7M | $622.7M | $675.2M | $1.11B | $747.7M | $447.6M | $173.5M | $437.9M |
| Invested capital | $503.0M | −$314.4M | −$258.6M | −$363.7M | $224.3M | $1.1M | −$64.5M | $149.2M | $139.0M | −$24.1M |
| Tangible asset value | −$293.0M | $39.6M | $64.7M | $148.0M | $747.4M | $978.9M | $480.4M | $435.3M | $197.5M | $474.0M |
| Net current asset value | −$654.0M | −$424.0M | −$483.4M | −$309.1M | $256.8M | $690.1M | $369.3M | $411.7M | $137.2M | $431.5M |
| Graham net-net per share | −$7.78 | −$5.71 | −$7.70 | −$5.74 | $2.68 | $10.19 | $5.37 | $7.28 | $3.33 | $10.90 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 0.9% | 1.3% | 10.8% | 40.2% | 20.8% | 16.2% | 23.9% | 7.9% | 106.9% | 7,660.2% |
| Capex / depreciation | 0.17 | 0.21 | 1.80 | 8.02 | 5.52 | 3.58 | 2.91 | 0.21 | 0.48 | 2.98 |
| Stock-based compensation / revenue | 22.7% | 28.2% | 31.1% | 35.9% | 29.9% | 31.6% | 79.1% | 155.6% | 2,603.9% | 36,322.6% |
| R&D / revenue | 111.4% | 124.6% | 149.3% | 194.3% | 141.5% | 152.0% | 344.6% | 570.9% | 8,868.5% | 137,747.4% |
| SG&A / revenue | 51.9% | 57.4% | 71.3% | 76.6% | 62.6% | 67.5% | 155.7% | 248.0% | 3,825.0% | 48,824.1% |
| Efficiency | ||||||||||
| Days sales outstanding | 76.1 | 63.6 | 47.8 | 42.6 | 35.1 | 37.7 | 80.2 | 63.5 | 722.7 | — |
| Days of inventory on hand | 162.4 | 187.8 | 245.2 | 277.1 | 333.8 | 732.3 | 377.1 | 1,245.7 | 138,152.5 | — |
| Days payables outstanding | 116.8 | 192.4 | 344.7 | 389.3 | 342.7 | 768.1 | 509.5 | 3,369.9 | 2,600,625.0 | 8.3 |
| Cash conversion cycle (days) | 121.8 | 59.1 | -51.7 | -69.6 | 26.2 | 1.9 | -52.2 | -2,060.7 | -2,461,749.8 | — |
| Receivables turnover | 4.79 | 5.74 | 7.63 | 8.56 | 10.41 | 9.69 | 4.55 | 5.75 | 0.51 | — |
| Payables turnover | 3.13 | 1.90 | 1.06 | 0.94 | 1.07 | 0.48 | 0.72 | 0.11 | 0.00 | 44.11 |
| Inventory turnover | 2.25 | 1.94 | 1.49 | 1.32 | 1.09 | 0.50 | 0.97 | 0.29 | 0.00 | — |
| Asset turnover | 0.44 | 0.37 | 0.29 | 0.24 | 0.21 | 0.19 | 0.11 | 0.09 | 0.01 | 0.00 |
| Average receivables | $140.4M | $97.6M | $56.9M | $42.4M | $33.8M | $28.0M | $22.8M | $9.0M | $5.2M | — |
| Average payables | $34.9M | $40.4M | $42.7M | $30.2M | $15.0M | $12.9M | $12.6M | $10.6M | $7.1M | $4.2M |
| Average inventory | $48.5M | $39.5M | $30.4M | $21.5M | $14.6M | $12.3M | $9.3M | $3.9M | $378,500 | $0 |
| Intangibles / total assets | 14.4% | 14.8% | 14.1% | 13.2% | 11.5% | 10.0% | 15.3% | 24.1% | 37.9% | 0.0% |
Computed from RARE's annual financial statements (latest annual report filed February 18, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RARE valuation and financial ratios
Ultragenyx Pharmaceutical earned a return on invested capital of −448.2% in fiscal 2025. It ended the year with $1.3 billion of debt and $693.0 million in cash and short-term investments, net debt of $583.0 million. The share count rose 149.1% from 39.6M to 98.6M over 9 years.
See the RARE income statement, the RARE chart for price history, or the RARE stock overview for the latest quote and news.
RARE key metrics FAQ
What is Ultragenyx Pharmaceutical's ROIC?
Ultragenyx Pharmaceutical's return on invested capital was −448.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical had total debt of $1.3 billion at the end of fiscal 2025.
What is Ultragenyx Pharmaceutical's free cash flow yield?
Ultragenyx Pharmaceutical generated -$472.0 million of free cash flow in fiscal 2025, a free cash flow yield of −20.8% on its market value at year-end ($2.3 billion).
What is Ultragenyx Pharmaceutical's current ratio?
Ultragenyx Pharmaceutical's current ratio was 2.48 at the end of fiscal 2025: current assets were 2.48 times current liabilities.